<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328260</url>
  </required_header>
  <id_info>
    <org_study_id>APM-05</org_study_id>
    <nct_id>NCT03328260</nct_id>
  </id_info>
  <brief_title>High Intensity Focused Ultrasound in Uterine Myoma</brief_title>
  <official_title>Prospective, Muti-institute, Single Arm, Confirmative Trial Evaluating Efficacy and Safety of High Intensity Focused Ultrasound Device (RODIN) in Women With Symptomatic Uterine Leiomyoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALPINION Medical Systems</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim to evaluate the efficacy of safety of newly developed, high intensity focused ultrasound
      device in women with symptomatic uterine leiomyoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non perfused volume</measure>
    <time_frame>treatment day</time_frame>
    <description>Non perfused volume in myoma immediately after ablation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIFU</intervention_name>
    <description>Transvaginal high intensity focused ultrasound to ablate uterine myoma</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal (FSH &lt; 40 IU/L)

          -  Symptomatic uterine fibroids

          -  Willing to contracept during study period

        Exclusion Criteria:

          -  Pregnant or willing to be pregnant in future

          -  Cancer in female reproductive organ is suspected or diagnosed

          -  Inflammation in female reproductive organ

          -  Poorly controlled systemic disease

          -  Hematocrit &lt; 25%

          -  Glomerular filtration rate(GFR) &lt;= 30ml/min

          -  Cannot tolerate contrast-enhanced MR or Contrast-enhanced ultrasound(CEUS)

          -  Cannot lie down

          -  Previous treatment for leiomyoma, any of ① myolysis, ② myomectomy within 1 year, ③
             hormonal therapy longer than 7 days within 4 weeks

          -  Cannot count the number or measure volume of leiomyoma using MRI

          -  Leiomyomas are inadequate (location, volume, number) for intervention

          -  Diameter of leiomyoma is over 5 cm

          -  Leiomyoma is not enhanced

          -  Lactating women

          -  Cannot communicate properly

          -  Participating or have participated in other trials within 30 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam Si</city>
        <state>Gyenggi DO</state>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

